NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $214,372 | +1.9% | 359,925 | -1.6% | 0.00% | – |
| Q2 2023 | $210,438 | -83.2% | 365,853 | -79.5% | 0.00% | – |
| Q1 2023 | $1,254,304 | -70.3% | 1,784,471 | -4.4% | 0.00% | -100.0% |
| Q4 2022 | $4,220,583 | -29.4% | 1,867,514 | +0.0% | 0.00% | 0.0% |
| Q3 2022 | $5,976,000 | +76.3% | 1,867,147 | +109.2% | 0.00% | 0.0% |
| Q2 2022 | $3,390,000 | -35.4% | 892,352 | -8.3% | 0.00% | 0.0% |
| Q1 2022 | $5,245,000 | -61.7% | 973,069 | -3.9% | 0.00% | -50.0% |
| Q4 2021 | $13,684,000 | -49.1% | 1,012,943 | -32.4% | 0.00% | -60.0% |
| Q3 2021 | $26,893,000 | +7.0% | 1,497,388 | +2.3% | 0.01% | +25.0% |
| Q2 2021 | $25,127,000 | -17.1% | 1,464,342 | -3.4% | 0.00% | -33.3% |
| Q1 2021 | $30,319,000 | +28.6% | 1,515,952 | +9.3% | 0.01% | +20.0% |
| Q4 2020 | $23,569,000 | -0.1% | 1,386,373 | -2.5% | 0.01% | 0.0% |
| Q3 2020 | $23,602,000 | -30.9% | 1,422,594 | -3.6% | 0.01% | -37.5% |
| Q2 2020 | $34,176,000 | +31.1% | 1,475,675 | +1.0% | 0.01% | +14.3% |
| Q1 2020 | $26,068,000 | -14.8% | 1,460,454 | +3.1% | 0.01% | 0.0% |
| Q4 2019 | $30,589,000 | -16.2% | 1,417,164 | -29.3% | 0.01% | -22.2% |
| Q3 2019 | $36,513,000 | -48.1% | 2,004,571 | +1.4% | 0.01% | -47.1% |
| Q2 2019 | $70,306,000 | +13.9% | 1,975,980 | +7.5% | 0.02% | +13.3% |
| Q1 2019 | $61,739,000 | +4.7% | 1,837,456 | +2.4% | 0.02% | -11.8% |
| Q4 2018 | $58,983,000 | -46.2% | 1,794,444 | -0.2% | 0.02% | -37.0% |
| Q3 2018 | $109,599,000 | +34.1% | 1,797,889 | +7.4% | 0.03% | +28.6% |
| Q2 2018 | $81,720,000 | -70.5% | 1,673,558 | -35.8% | 0.02% | -70.8% |
| Q1 2018 | $276,893,000 | +146.4% | 2,605,818 | +38.5% | 0.07% | +157.1% |
| Q4 2017 | $112,384,000 | +144.0% | 1,881,851 | -2.0% | 0.03% | +133.3% |
| Q3 2017 | $46,066,000 | +21.6% | 1,919,412 | -0.9% | 0.01% | +9.1% |
| Q2 2017 | $37,877,000 | -10.7% | 1,937,352 | +7.2% | 0.01% | -8.3% |
| Q1 2017 | $42,410,000 | +95.7% | 1,807,058 | +2.3% | 0.01% | +71.4% |
| Q4 2016 | $21,675,000 | -19.6% | 1,766,465 | +12.5% | 0.01% | -12.5% |
| Q3 2016 | $26,965,000 | +20.6% | 1,569,592 | -0.1% | 0.01% | +14.3% |
| Q2 2016 | $22,363,000 | +2.5% | 1,571,599 | -1.0% | 0.01% | 0.0% |
| Q1 2016 | $21,823,000 | -17.1% | 1,587,855 | +1.7% | 0.01% | -22.2% |
| Q4 2015 | $26,318,000 | +57.5% | 1,561,947 | +2.4% | 0.01% | +50.0% |
| Q3 2015 | $16,715,000 | -4.5% | 1,525,085 | +9.0% | 0.01% | +20.0% |
| Q2 2015 | $17,511,000 | +11.4% | 1,399,743 | -2.1% | 0.01% | 0.0% |
| Q1 2015 | $15,720,000 | -28.0% | 1,429,074 | +1.5% | 0.01% | -28.6% |
| Q4 2014 | $21,822,000 | +24.7% | 1,407,807 | -2.9% | 0.01% | +40.0% |
| Q3 2014 | $17,504,000 | -10.1% | 1,450,229 | -4.5% | 0.01% | -16.7% |
| Q2 2014 | $19,470,000 | -3.1% | 1,518,748 | -8.4% | 0.01% | 0.0% |
| Q1 2014 | $20,099,000 | +6.1% | 1,658,285 | -0.6% | 0.01% | 0.0% |
| Q4 2013 | $18,939,000 | +10.7% | 1,668,618 | +1.9% | 0.01% | 0.0% |
| Q3 2013 | $17,106,000 | -10.3% | 1,637,714 | -0.9% | 0.01% | -14.3% |
| Q2 2013 | $19,080,000 | – | 1,651,953 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |